Treatment with upadacitinib or abrocitinib, oral selective JAK-1 inhibitors, resulted in significant clinical benefit in moderate-to-severe AD patients and was well tolerated [134,135,136,137,138]. Here, JAK1 is linked to Alzheimer disease.